Moderate To Severe Hidradenitis Suppurativa clinical trials

Explore recruiting moderate to severe hidradenitis suppurativa clinical trials.

Recruiting moderate to severe hidradenitis suppurativa studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Moderate To Severe Hidradenitis Suppurativa trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa

Hungary, Spain, France, Belgium, Sweden, Germany +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa

Hungary, Austria, Germany, France, Spain, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants with Moderate to Severe Hidradenitis Suppurativa

Germany, Poland, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

A Seamless Phase 2a/2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa

Germany, Italy, Ireland, Poland, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa

Poland, Hungary, Netherlands, Germany, Czechia, Spain +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study of NAV-240 in Adult Participants with Moderate-to-Severe Hidradenitis Suppurativa

Hungary, Poland, Germany, Bulgaria, Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

Moderate To Severe Hidradenitis Suppurativa trials by city

Moderate To Severe Hidradenitis Suppurativa in Toronto Moderate To Severe Hidradenitis Suppurativa in Vancouver Moderate To Severe Hidradenitis Suppurativa in Montreal Moderate To Severe Hidradenitis Suppurativa in Calgary Moderate To Severe Hidradenitis Suppurativa in Edmonton Moderate To Severe Hidradenitis Suppurativa in Ottawa Moderate To Severe Hidradenitis Suppurativa in Winnipeg Moderate To Severe Hidradenitis Suppurativa in Quebec City Moderate To Severe Hidradenitis Suppurativa in Hamilton Moderate To Severe Hidradenitis Suppurativa in Kitchener Moderate To Severe Hidradenitis Suppurativa in London Moderate To Severe Hidradenitis Suppurativa in Halifax Moderate To Severe Hidradenitis Suppurativa in New York Moderate To Severe Hidradenitis Suppurativa in Los Angeles Moderate To Severe Hidradenitis Suppurativa in Chicago Moderate To Severe Hidradenitis Suppurativa in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease